Liposomal Clodronate as a Therapy for Autoimmune Hemolytic Anemia
Tech ID: 02-07
NOTE: THIS TECHNOLOGY IS EXPERIMENTAL AND THEREFORE IT IS NOT AVAILABLE TO HUMANS. IT HAS ONLY BEEN TESTED IN MICE AND DOGS DIAGNOSED WITH AIHA
Summary - This invention is using liposomal clodronate as a therapy for autoimmune hemolytic anemia (AIHA).
- Therapy for autoimmune hemolytic anemia
- The therapy is applicable to both humans and companion animals
Advantages of Invention
- The method is less invasive than surgery (splenectomy)
- Decrease use of steroids
- Decrease side effects
State of Development
- The efficacy of this therapy has been demonstrated by some strong in vivo data obtained in mice and dogs with AIHA.
- Using a mouse model in which animals were given anti red blood cell antibodies, treatment with liposomal clodronate substantially decreased red blood cell destruction.
- In addition, this effect was detected within hours and lasted at least a week.
Further R&D Required - Additional in vivo studies with other animal models.
Licensing Potential - Available for licensing.
Inventors - Mike Jordan, MD, Philippa Marrack, PhD and John Kappler, PhD
Patent Status - U.S. Patent #7,090,865
RBC clearance and the effects of LC treatment in dogs with AIHA. RBC clearance in 6 dogs with spontaneous AIHA was assessed by flow cytometry prior to treatment and again 24 hours after treatment with LC and the mean (± SE) percentage of labeled RBC present in circulation at each time point post infusion was determined. (B) RBC clearance kinetics were determined again 24 hours after treatment with 0.5 mL/kg LC. In 4 dogs (Nonresponders), there was no change in RBC clearance compared to clearance prior to treatment with LC, whereas in 2 dogs (Responders), RBC clearance was markedly reduced.
For Further Information, Contact:
Emmanuel Hilaire, PhD
Technology Transfer Office
National Jewish Health
1400 Jackson Street, Room M206b
Denver, CO 80206
Voice: (303) 398-1262
Fax: (303) 270-2352